Despite substantial progress in the past two decades, cancer remains the leading cause of death by disease in US children between 1 and 15 years of age. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and cure rates are approaching ~ 80% today. Unfortunately, 20% of children with ALL are not cured with current therapy, making the number of cases of relapsed ALL greater than the total number of new cases of most childhood cancers. Previous work has established that de novo drug resistance is a primary cause of treatment failure in childhood ALL. However, the genomic determinants of drug resistance remain poorly defined. The research supported by this MERIT award has focused on elucidating the genomic determinants of inter-patient differences in drug response in children with ALL, leading to a number of new insights into the pharmacogenomics of childhood ALL. Our scientific aims are focused on some of the most widely used antileukemic agents, thiopurines and glucocorticoids (with complementary studies of L- asparaginase and vincristine).
The first aim i s to identify genes that influence the response to thiopurines (mercaptopurine, thioguanine), using genomewide approaches for gene expression analyses of ALL cells, and SNP analyses of germline and ALL cell DNA to identify SNPs and copy number variations (CNVs) that are significantly related to drug sensitivity and response. Studies in Aim 2 are designed to elucidate these pharmacogenomic traits in T-ALL, a less common subtype that is more resistant to curative chemotherapy, and compare these findings to B-lineage ALL. Once we identify these genes or genome abnormalities (SNPs, CNVs) influencing ALL drug resistance and treatment response, we perform biochemical and genomic studies to determine the mechanism by which these genes or their variants influence the sensitivity of ALL cells to these chemotherapeutic agents. In the continuation of this research program, we are extending our findings from the last 4 years of funding by exploiting new genomewide strategies to identify genomic determinants of drug response (e.g., 1 million SNP arrays, gene expression arrays, mIRNA arrays), to determine whether CNVs or specific mlRNAs modify the expression of genes and thereby alter the sensitivity of ALL cells to these chemotherapeutic agents. Our preliminary findings have indeed revealed specific mlRNAs that influence the sensitivity of ALL cells to these agents, and we have also recently discovered that specific CNVs in ALL cells can significantly influence drug resistance. The continuation of these studies will provide important new insights into the genomic determinants of treatment failure and point to novel targets for developing strategies to overcome drug resistance in childhood ALL.
Pharmacogenomics has great potential to improve public health by minimizing drug-induced side events and improving treatment effectiveness. Acute lymphoblastic leukemia (ALL) the most common cancer in children, serves as a paradigm for a chemotherapy-sensitive malignancy. By capitalizing on the genomic studies which we have already conducted in children with ALL, and exploiting new genomewide technologies, we will define genomic polymorphisms that can be used to design less toxic and more efficacious cancer treatment regimens.
|Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53|
|Hoffman, James M; Haidar, Cyrine E; Wilkinson, Mark R et al. (2014) PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet 166C:45-55|
|Bhojwani, Deepa; Sabin, Noah D; Pei, Deqing et al. (2014) Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 32:949-59|
|Roberts, Kathryn G; Pei, Deqing; Campana, Dario et al. (2014) Outcomes of children with BCR-ABL1ýýýlike acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 32:3012-20|
|Fernandez, Christian A; Smith, Colton; Yang, Wenjian et al. (2014) HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 124:1266-76|
|Bell, Gillian C; Crews, Kristine R; Wilkinson, Mark R et al. (2014) Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 21:e93-9|
|Roberts, Kathryn G; Pei, Deqing; Campana, Dario et al. (2014) Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 32:3012-20|
|Fernandez, C A; Stewart, E; Panetta, J C et al. (2014) Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol 73:1307-13|
|Hicks, J Kevin; Crews, Kristine R; Flynn, Patricia et al. (2014) Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics 15:1065-78|
|Aries, I M; van den Dungen, E S R; Pieters, R et al. (2014) The NR4A orphan nuclear receptors do not confer prednisolone resistance in pediatric acute lymphoblastic leukemia. Leukemia 28:422-5|
Showing the most recent 10 out of 193 publications